Alice T. Shaw, MD, PhD

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.

Alice T. Shaw, MD, PhD, discusses using crizotinib to treat patients with ALK-positive lung cancer.

Alice T. Shaw, MD, PhD, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.

Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.